At a Glance

Company information

Company name Astellas Pharma Inc.
Headquarters 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan
Tel. +81-3-3244-3000
Access Map (Google Maps)
Foundation 1923
Capital 103,001 million yen (March 2022)
Representative Director Kenji Yasukawa (President and Chief Executive Officer)
Employees 14,522 (Consolidated, March 2022)
Business Description Manufacturing, marketing, and import/export of pharmaceuticals.

 

Business development on a global scale

Astellas was formed in 2005 after the merger of Yamanouchi Pharmaceutical Co., Ltd. and the Fujisawa Pharmaceutical Co., Ltd. "Astellas" expresses the idea of "aspired stars" and “advanced stars” and is derived from the Latin word "stella," Greek "aster," and English "stellar," which all refer to "stars." 'The name is also connected to the Japanese phrase, "make tomorrow shine."

With R&D and manufacturing bases in Japan, Europe, the U.S., and Asia, we are expanding our business in more than 70 countries and regions worldwide.
 

Business development on a global scale

※The data is based on metrics from the end of the fiscal year ending March 31, 2022. Commercial segment of Australia was changed from Established Markets to International Markets in Q3/FY2022.
 

 R&D Bases



 

Creating VALUE through cutting-edge science

Astellas' VISION, "on the forefront of healthcare change to turn innovative science into VALUE for patients," drives our pursuit of innovative healthcare solutions. In order to deliver significant VALUE to society, Astellas maintains a high ratio of R&D expenses to revenue (19%) and will continue to make necessary investments for further growth. Of the many R&D programs Astellas has underway, 24 are related to our Rx (prescription drug) business. We also advance Rx+® business, which aims to contribute to patients across the whole patient journey (overall medical care, including diagnostic, preventive, therapeutic and prognostic care).
 

Creating VALUE through cutting-edge science


*All data is based on metrics from the end of the fiscal year ending March 31, 2022.

 

Valuing a diverse workforce

The realization of our VISION is only possible by maximizing the strength of our people; therefore, Astellas regards investment in human resources as an essential factor in shaping the future of our organization. To that end, we are focusing on creating an environment that maximizes the power of our workforce. 
In our Corporate Strategic Plan 2021 (CSP21), which covers the five years up to FY2025, we have newly set our Organizational Health Goals. By promoting innovation, optimizing our talent, and fostering collaboration, we aim to nurture a corporate culture that seeks to realize ambitious goals and enhances Astellas' ability to realize these goals.

We believe that by creating a more conducive workspace, we can bring together employees with diverse values, perspectives, backgrounds, and experiences to enhance one another in an environment of psychological safety. At Astellas, the human resources function in each region takes the lead in implementing diversity promotion measures tailored to the current situation in employees’ respective areas based on a globally shared concept of Diversity, Equity & Inclusion.
 

Valuing a diverse workforce

 

* Expatriate employees seconded within the Astellas corporate group are included in the headcount of their current location.
Expatriate employees seconded out of the Astellas corporate group are excluded from the headcount.
*All data is based on metrics from the end of the fiscal year ending March 31, 2022.

Astellas' talent development and investment